New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


Combination Therapy New Standard of Care for Squamous NSCLC

From ASCO Daily News Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival in patients with metastatic squamous non–small cell lung cancer (NSCLC), according to data…


New Combination Therapy Clinical Trial for UCLA

From UCLA Patient Newsletter, May/June Grant to Fund Clinical Trial for Late-Stage Lung Cancer UCLA has received a $12 million grant from the California Institute for Regenerative Medicine (CIRM), which will fund a new phase 1…


New Noninvasive Method for Lung Cancer Screening

From ASCO Daily News Comprehensive sequencing of plasma cell-free DNA (cfDNA) demonstrates the ability to non-invasively detect lung cancer with reliable specificity and sensitivity, according to preliminary data from the Circulating Cel…


Why non-smokers are getting lung cancer

from Lung cancer is commonly associated with smoking. But rates of the disease among non-smokers – and women – are rising. As a lung cancer researcher and patient advocate at Trinity College Dublin, Anne-Marie Baird gets mixed r…


Lung Cancer Research gains $6,000,000 for 2019

From CSPAN > AMENDMENT NO. 11 OFFERED BY MR. NOLAN The Acting CHAIR. It is now in order to consider amendment No. 11 printed in House Report 115–785. Mr. NOLAN. Mr. Chairman, I have an amendment at the desk. The Acting…


Combination Therapy for Small Cell Lung Cancer

From Yahoo Finance Combination Therapy for Small Cell Lung Cancer gets positive results in this new Phase III study. Genentech, a member of the Roche Group, today announced that the Phase III IMpower133 study met its co-primary endpoints of…


Study: Keytruda better than chemo against advanced lung cancer

From UPI A cancer drug that boosts the immune system outperforms chemotherapy in fighting advanced lung cancer, a new trial shows. Keytruda, or pembrolizumab, extended life four to eight months longer than chemotherapy in lung cancer pati…


New research finds lung cancer risk drops substantially within five years of quitting smoking

from Research News @ Vanderbilt Just because you stopped smoking years ago doesn’t mean you’re out of the woods when it comes to developing lung cancer.  That’s the “bad” news. The good news is your risk of lung cancer drops subst…


Low Lung Cancer Screening Rate

from OncLive A total 1.9% of more than 7.6 million current and former heavy smokers in the United States underwent lung cancer screening in 2016, suggesting that it remains inadequate despite recommendations from the United States Preven…


Immunotherapy Combination Increases Lung Cancer Survival

from WHTC Radio Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim resu…

Read More